Objective：This study aims to retrospectively analyze the effects of low and medium-dose glucocorticoids in treating of severe corona virus disease-2019 （COVID-19）. Methods：A retrospective analysis of the clinical data of 95 patients with severe COVID-19 admitted to the Huangshi Hospital of Traditional Chinese Medicine assisted by the Huangshi Medical Team of the Affiliated Sir Run Run Hospital of Nanjing Medical University from Feb，15th，2020 to Mar，20th，2020 was conducted. Control group（conventional treatment，33 cases）or hormone treatment group（conventional treatment combined glucocorticoid，62 cases）were divided according to whether using glucocorticoids or not. Laboratory test results，time of clinical symptoms relieved，the 28-day mortality rate，severe to critical convention rate，hospitalization days，inflammation index，improvement of oxygenation index，imaging changes and the occurrence of adverse reactions were compared between the two groups. Results：In general clinical data，the lymphocyte count and monocyte count from the hormone treatment group were significantly lower than that from the control group（P < 0.05），and there was no significant difference in the remaining baseline clinical data between the two groups. Compared with the control group，the clinical symptom relief time from hormone treatment group was significantly shorter［9.50（5.00，14.50）d vs. 16.00（5.00，21.00）d，P ＜ 0.001］，the conversion rate of severe to critical illness was significantly reduced［12.90% vs. 33.33%，P=0.029］，and the time of hospital stay was significantly shortened［20.00（16.00，22.00）d vs. 24.00（20.50，26.50）d，P=0.002］，the 28-day mortality rate was not increased［6.45% vs. 9.09%，P=0.691］. The oxygenation index recovery increased，the inflammatory factors of C-reactive protein and IL-6 decreased，and the imaging absorption speed increased significantly. There was no significant difference in adverse reactions between the two groups. Conclusion：Low and medium-dose glucocorticoids can significantly shorten the clinical symptom relief time of patients with severe COVID-19，improve oxygenation，promote lung lesion absorption，and have not obvious adverse reactions. It can be used in a short course during the treatment of severe COVID-19.